Targeting CD133 in an in vivo ovarian cancer model reduces ovarian cancer progression

OBJECTIVES: While most women with ovarian cancer will achieve complete remission after treatment, the majority will relapse within two years, highlighting the need for novel therapies. Cancer stem cells (CSC) have been identified in ovarian cancer and most other carcinomas as a small population of c...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Skubitz, Amy P.N., Taras, Elizabeth P., Boylan, Kristin L.M., Waldron, Nate N., Oh, Seunguk, Panoskaltsis-Mortari, Angela, Vallera, Daniel A.
Médium: Artigo
Jazyk:Inglês
Vydáno: 2013
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3906852/
https://ncbi.nlm.nih.gov/pubmed/23721800
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ygyno.2013.05.027
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky